Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Inavolisib plus Fulvestrant versus Alpelisib plus Fulvestrant in HR-positive, HER2-negative, PIK3CA-mutated locally advanced or metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Fulvestrant (fulvestrant)
• Inavolisib (Inavolisib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING